Species distribution and antifungal susceptibility of Aspergillus clinical isolates in Lebanon

Future Microbiol. 2021 Jan;16(1):13-26. doi: 10.2217/fmb-2020-0141.

Abstract

Aim: We sought to provide first insights into the epidemiology and antifungal susceptibility patterns of the aspergilli in Lebanon. Materials & methods: After species identification, antifungal susceptibility was investigated according to EUCAST recommendations. CYP51A gene was sequenced in resistant isolates and its expression level was evaluated by Reverse transcription-quantitative PCR. Results: Among the 73 Aspergillus isolates studied (mostly from ears), the predominant species was Aspergillus niger (54.8%). The overall drug resistance was highest for amphotericin B (38.4%), followed by itraconazole (31.5%), posaconazole (30.1%) and voriconazole (23.3%). In addition, CYP51A gene mutations were not the major cause of azole resistance among these isolates. Conclusion: Our findings indicate the paramount need for an integral One Health strategy and a national reference center for invasive mycoses and antifungals.

Keywords: Aspergillus spp.; CYP51A; Lebanon; antifungal susceptibility; clinical settings; epidemiology.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Amphotericin B / pharmacology
  • Antifungal Agents / pharmacology*
  • Aspergillosis / microbiology*
  • Aspergillus / classification
  • Aspergillus / drug effects*
  • Aspergillus / genetics
  • Aspergillus / isolation & purification
  • Child
  • Drug Resistance, Fungal
  • Female
  • Fungal Proteins / genetics
  • Fungal Proteins / metabolism
  • Humans
  • Itraconazole / pharmacology
  • Lebanon
  • Male
  • Microbial Sensitivity Tests
  • Middle Aged
  • Voriconazole / pharmacology
  • Young Adult

Substances

  • Antifungal Agents
  • Fungal Proteins
  • Itraconazole
  • Amphotericin B
  • Voriconazole